LISINOPRIL AND HYDROCHLOROTHIAZIDE Drug Patent Profile
✉ Email this page to a colleague
When do Lisinopril And Hydrochlorothiazide patents expire, and what generic alternatives are available?
Lisinopril And Hydrochlorothiazide is a drug marketed by Aurobindo, Chartwell Rx, Corepharma, Epic Pharma Llc, Hikma Intl Pharms, Invagen Pharms, Lupin, Norvium Bioscience, Prinston Inc, Sandoz, Sun Pharm Inds Ltd, Teva, and Watson Labs. and is included in thirteen NDAs.
The generic ingredient in LISINOPRIL AND HYDROCHLOROTHIAZIDE is hydrochlorothiazide; lisinopril. There are thirty-two drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; lisinopril profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LISINOPRIL AND HYDROCHLOROTHIAZIDE?
- What are the global sales for LISINOPRIL AND HYDROCHLOROTHIAZIDE?
- What is Average Wholesale Price for LISINOPRIL AND HYDROCHLOROTHIAZIDE?
Summary for LISINOPRIL AND HYDROCHLOROTHIAZIDE
US Patents: | 0 |
Applicants: | 13 |
NDAs: | 13 |
Finished Product Suppliers / Packagers: | 33 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Clinical Trials: | 12 |
DailyMed Link: | LISINOPRIL AND HYDROCHLOROTHIAZIDE at DailyMed |
Recent Clinical Trials for LISINOPRIL AND HYDROCHLOROTHIAZIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
The University of Texas Health Science Center, Houston | Phase 4 |
IPCA Laboratories Ltd. | Phase 1 |
Scripps Translational Science Institute | N/A |
Pharmacology for LISINOPRIL AND HYDROCHLOROTHIAZIDE
Drug Class | Angiotensin Converting Enzyme Inhibitor Thiazide Diuretic |
Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
Physiological Effect | Increased Diuresis |